NCT03448172View on ClinicalTrials.gov

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

May 26, 2018

Study Completion Date

June 13, 2018

Conditions
Healthy
Interventions
DRUG

[14C]PF-05221304

a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)

Trial Locations (1)

53704

Covance Clinical Research Unit Inc., Madison

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03448172 - Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter